All PlansCoverageMedium impact
Myeloperoxidase (MPO) Immunoassay for Cardiac Disease Risk
Blue Cross & Blue Shield of Mississippi·Cardiology, Emergency Medicine, Internal Medicine +1 more·Medical Policy
Effective date
Dec 16, 2024
We identified it
Jun 20, 2026
Summary
This policy confirms that Myeloperoxidase (MPO) immunoassay testing for cardiac disease risk assessment remains classified as investigational and is not covered. The policy was reviewed on 12/16/2024 with no changes, maintaining the investigational status that has been in place since 2013.
Action Required
Immediately: Billing team must ensure CPT code 83876 (Myeloperoxidase MPO) is flagged as non-covered/investigational in billing system. Verify claims for this code are not submitted as they will be denied. Educate providers that MPO testing for cardiac risk assessment is considered investigational and not reimbursable.